As per the research report, the size of the Europe Methadone Market was valued at USD xx billion in 2020 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2025 during the forecast period 2020-2025.
Methadone is an opioid, which is sold under the name of Dolophine among others. It is used in treating pain and as maintenance therapy and to help with tapering in people suffering from opioid dependence.
Methadone helps in reducing withdrawal symptoms and cravings in people with opioid addiction. Also, it helps in blocking the high sensation in parts of the spinal cord and brain which are caused by using opiates. Methadone helps in managing additions in patients who are dependent on morphine, heroin, or prescription painkillers. It can be used for long or short durations which depends on the necessity of the patient.
The driving factors of European Methadone market are growth in the number of people who are addicted to several opioids such as morphine and heroin. Also, growth in awareness towards the use of these medications and growth in a number of people who are seeking help to detoxify their system boosts the market growth. Additionally, since the medication can be used for managing pain, growth in the number of people affected with chronic pain is presumed to raise the demand for this drug. However, the market is constrained due to factors such as side-effects which are caused by the usage of methadone.
This research report segmented and sub-segmented into the following categories:
Europe has the second-largest market for methadone in the world by shareFactors such as the rising incidence of addiction and growing incidence of people using methadone for chronic pains are expected to drive the market growth in the region.
Key players operating in the European Methadone Market profiled in this report are Diskets, Methadoes, Aurolife Pharma LLC, Macfarlan Smith, VistaPharm, Qinghai Pharm, CentralPharm, Mallinckrodt, and Roxane (Boehringer Ingelheim) among others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Application
5.1.1 Operation
5.1.2 Detoxification
5.1.3 Others
5.1.4 Y-o-Y Growth Analysis, By Application
5.1.5 Market Attractiveness Analysis, By Application
5.1.6 Market Share Analysis, By Application
5.2 Mode of Administration
5.2.1 Injections
5.2.2 Oral Medicine
5.2.2.1 Tablets
5.2.2.2 Liquid
5.2.3 Y-o-Y Growth Analysis, By Mode of Administration
5.2.4 Market Attractiveness Analysis, By Mode of Administration
5.2.5 Market Share Analysis, By Mode of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Application
6.1.3.2 By Mode of Administration
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Application
6.1.4.2 By Mode of Administration
6.1.5 Market Share Analysis
6.1.5.1 By Application
6.1.5.2 By Mode of Administration
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Diskets
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Methadoes
8.3 Aurolife Pharma LLC
8.4 Macfarlan Smith
8.5 VistaPharm
8.6 Qinghai Pharm
8.7 CentralPharm
8.8 Mallinckrodt
8.9 Roxane
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
